Global Kinase Inhibitors
Global Kinase Inhibitors

Kinase Inhibitors Comprehensive Study by Type (Tyrosin Kinase Inhibitors (TKI), Receptor Tyrosine Kinase Inhibitors, Non-Receptor Tyrosine Kinase Inhibitors, Mulikinase Inhibitors, Threonine Kinase Inhibitor, RHO Kinase Inhibitors, Cyclin Dependant Kinase Inhibitor, Aurora Kinase Inhibitors, MAP/MEK Kinase Inhibitors, Others), Application (Lung Cancer, Breast Cancer, Renal Cell Cancer, Others), End User (Pharmaceutical companies, Private and Government research institutes, Academic Institutes, Healthcare facilities) Players and Region - Global Market Outlook to 2024

Kinase Inhibitors Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Jun 2019 Edition 231 Pages 198 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study
A protein kinase inhibitor refers to the type of enzyme inhibitor which blocks the action of one or more protein kinases and considered as a potential help for preventing the growth of cancerous cells. The increasing number of cancer patients driving the demand for novel treatment. According to the World Health Organization (WHO), cancer led to 9.6 million deaths in 2018 globally. Further, growing healthcare infrastructure in the developing economies and emphasizing on advanced treatment for cancer expected to drive the demand for kinase inhibitors over the forecasted period.

The market study is being classified by Type (Tyrosin Kinase Inhibitors (TKI), Receptor Tyrosine Kinase Inhibitors, Non-Receptor Tyrosine Kinase Inhibitors, Mulikinase Inhibitors, Threonine Kinase Inhibitor, RHO Kinase Inhibitors, Cyclin Dependant Kinase Inhibitor, Aurora Kinase Inhibitors, MAP/MEK Kinase Inhibitors and Others), by Application (Lung Cancer, Breast Cancer, Renal Cell Cancer and Others) and major geographies with country level break-up.

Roche Holding AG (Switzerland), Novartis (Switzerland), AstraZeneca (United Kingdom), Bayer (Germany), Pfizer (United States), GlaxoSmithKline (United Kingdom), Bristol-Myers Squibb (United States), Cytrx Corporation (United States), Eisai Inc. (United States) and Merck Serono SA (Switzerland) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Eton Bioscience Inc. (United States) and Inhibikase Therapeutics, Inc. (United States).

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Kinase Inhibitors market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Kinase Inhibitors market by Type, Application and Region.

On the basis of geography, the market of Kinase Inhibitors has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Pharmaceutical companies will boost the Kinase Inhibitors market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Number of Cancer Patients
  • Rising Applications of Kinase Inhibitors in Cancer Therapies

Market Trend
  • Rising Adoption of Advanced Technologies for Cancer Treatment
  • Technological Advancement in the Healthcare Industry

Restraints
  • Stringent Government Regulations Regarding Approval Procedure
  • High Cost of Cancer Treatment

Opportunities
  • Rise in Number of Clinical Trials
  • Increasing Demand from the Developing Economies

Challenges
  • Lack of Advanced Healthcare Infrastructure in the Low and Middle Income Group Countries



“The US FDA has approved 48 small molecule protein kinase inhibitors, nearly all of which are orally effective with the exceptions of netarsudil (which is given as an eye drop) and temsirolimus (which is given intravenously). Of the 48 approved drugs, the majority (25) target receptor protein-tyrosine kinases, ten target non-receptor protein-tyrosine kinases, and 13 target protein-serine/threonine protein kinases.”

Key Target Audience
Research Organizations, Potential Investors, Government Regulatory Authorities, Research and Development Companies and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Tyrosin Kinase Inhibitors (TKI)
  • Receptor Tyrosine Kinase Inhibitors
  • Non-Receptor Tyrosine Kinase Inhibitors
  • Mulikinase Inhibitors
  • Threonine Kinase Inhibitor
  • RHO Kinase Inhibitors
  • Cyclin Dependant Kinase Inhibitor
  • Aurora Kinase Inhibitors
  • MAP/MEK Kinase Inhibitors
  • Others
By Application
  • Lung Cancer
  • Breast Cancer
  • Renal Cell Cancer
  • Others
By End User
  • Pharmaceutical companies
  • Private and Government research institutes
  • Academic Institutes
  • Healthcare facilities

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Cancer Patients
      • 3.2.2. Rising Applications of Kinase Inhibitors in Cancer Therapies
    • 3.3. Market Challenges
      • 3.3.1. Lack of Advanced Healthcare Infrastructure in the Low and Middle Income Group Countries
    • 3.4. Market Trends
      • 3.4.1. Rising Adoption of Advanced Technologies for Cancer Treatment
      • 3.4.2. Technological Advancement in the Healthcare Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Kinase Inhibitors, by Type, Application, End User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Kinase Inhibitors (Value)
      • 5.2.1. Global Kinase Inhibitors by: Type (Value)
        • 5.2.1.1. Tyrosin Kinase Inhibitors (TKI)
        • 5.2.1.2. Receptor Tyrosine Kinase Inhibitors
        • 5.2.1.3. Non-Receptor Tyrosine Kinase Inhibitors
        • 5.2.1.4. Mulikinase Inhibitors
        • 5.2.1.5. Threonine Kinase Inhibitor
        • 5.2.1.6. RHO Kinase Inhibitors
        • 5.2.1.7. Cyclin Dependant Kinase Inhibitor
        • 5.2.1.8. Aurora Kinase Inhibitors
        • 5.2.1.9. MAP/MEK Kinase Inhibitors
        • 5.2.1.10. Others
      • 5.2.2. Global Kinase Inhibitors by: Application (Value)
        • 5.2.2.1. Lung Cancer
        • 5.2.2.2. Breast Cancer
        • 5.2.2.3. Renal Cell Cancer
        • 5.2.2.4. Others
      • 5.2.3. Global Kinase Inhibitors by: End User (Value)
        • 5.2.3.1. Pharmaceutical companies
        • 5.2.3.2. Private and Government research institutes
        • 5.2.3.3. Academic Institutes
        • 5.2.3.4. Healthcare facilities
      • 5.2.4. Global Kinase Inhibitors Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Kinase Inhibitors: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Holding AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol-Myers Squibb (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cytrx Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eisai Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck Serono SA (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Kinase Inhibitors Sale, by Type, Application, End User and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Kinase Inhibitors (Value)
      • 7.2.1. Global Kinase Inhibitors by: Type (Value)
        • 7.2.1.1. Tyrosin Kinase Inhibitors (TKI)
        • 7.2.1.2. Receptor Tyrosine Kinase Inhibitors
        • 7.2.1.3. Non-Receptor Tyrosine Kinase Inhibitors
        • 7.2.1.4. Mulikinase Inhibitors
        • 7.2.1.5. Threonine Kinase Inhibitor
        • 7.2.1.6. RHO Kinase Inhibitors
        • 7.2.1.7. Cyclin Dependant Kinase Inhibitor
        • 7.2.1.8. Aurora Kinase Inhibitors
        • 7.2.1.9. MAP/MEK Kinase Inhibitors
        • 7.2.1.10. Others
      • 7.2.2. Global Kinase Inhibitors by: Application (Value)
        • 7.2.2.1. Lung Cancer
        • 7.2.2.2. Breast Cancer
        • 7.2.2.3. Renal Cell Cancer
        • 7.2.2.4. Others
      • 7.2.3. Global Kinase Inhibitors by: End User (Value)
        • 7.2.3.1. Pharmaceutical companies
        • 7.2.3.2. Private and Government research institutes
        • 7.2.3.3. Academic Institutes
        • 7.2.3.4. Healthcare facilities
      • 7.2.4. Global Kinase Inhibitors Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Kinase Inhibitors: by Type(USD Million)
  • Table 2. Kinase Inhibitors Tyrosin Kinase Inhibitors (TKI) , by Region USD Million (2013-2018)
  • Table 3. Kinase Inhibitors Receptor Tyrosine Kinase Inhibitors , by Region USD Million (2013-2018)
  • Table 4. Kinase Inhibitors Non-Receptor Tyrosine Kinase Inhibitors , by Region USD Million (2013-2018)
  • Table 5. Kinase Inhibitors Mulikinase Inhibitors , by Region USD Million (2013-2018)
  • Table 6. Kinase Inhibitors Threonine Kinase Inhibitor , by Region USD Million (2013-2018)
  • Table 7. Kinase Inhibitors RHO Kinase Inhibitors , by Region USD Million (2013-2018)
  • Table 8. Kinase Inhibitors Cyclin Dependant Kinase Inhibitor , by Region USD Million (2013-2018)
  • Table 9. Kinase Inhibitors Aurora Kinase Inhibitors , by Region USD Million (2013-2018)
  • Table 10. Kinase Inhibitors MAP/MEK Kinase Inhibitors , by Region USD Million (2013-2018)
  • Table 11. Kinase Inhibitors Others , by Region USD Million (2013-2018)
  • Table 12. Kinase Inhibitors: by Application(USD Million)
  • Table 13. Kinase Inhibitors Lung Cancer , by Region USD Million (2013-2018)
  • Table 14. Kinase Inhibitors Breast Cancer , by Region USD Million (2013-2018)
  • Table 15. Kinase Inhibitors Renal Cell Cancer , by Region USD Million (2013-2018)
  • Table 16. Kinase Inhibitors Others , by Region USD Million (2013-2018)
  • Table 17. Kinase Inhibitors: by End User(USD Million)
  • Table 18. Kinase Inhibitors Pharmaceutical companies , by Region USD Million (2013-2018)
  • Table 19. Kinase Inhibitors Private and Government research institutes , by Region USD Million (2013-2018)
  • Table 20. Kinase Inhibitors Academic Institutes , by Region USD Million (2013-2018)
  • Table 21. Kinase Inhibitors Healthcare facilities , by Region USD Million (2013-2018)
  • Table 22. South America Kinase Inhibitors, by Country USD Million (2013-2018)
  • Table 23. South America Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 24. South America Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 25. South America Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 26. Brazil Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 27. Brazil Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 28. Brazil Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 29. Argentina Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 30. Argentina Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 31. Argentina Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 32. Rest of South America Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 33. Rest of South America Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 34. Rest of South America Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 35. Asia Pacific Kinase Inhibitors, by Country USD Million (2013-2018)
  • Table 36. Asia Pacific Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 37. Asia Pacific Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 38. Asia Pacific Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 39. China Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 40. China Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 41. China Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 42. Japan Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 43. Japan Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 44. Japan Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 45. India Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 46. India Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 47. India Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 48. South Korea Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 49. South Korea Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 50. South Korea Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 51. Taiwan Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 52. Taiwan Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 53. Taiwan Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 54. Australia Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 55. Australia Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 56. Australia Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 57. Rest of Asia-Pacific Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 58. Rest of Asia-Pacific Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 59. Rest of Asia-Pacific Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 60. Europe Kinase Inhibitors, by Country USD Million (2013-2018)
  • Table 61. Europe Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 62. Europe Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 63. Europe Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 64. Germany Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 65. Germany Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 66. Germany Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 67. France Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 68. France Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 69. France Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 70. Italy Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 71. Italy Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 72. Italy Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 73. United Kingdom Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 74. United Kingdom Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 75. United Kingdom Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 76. Netherlands Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 77. Netherlands Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 78. Netherlands Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 79. Rest of Europe Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 80. Rest of Europe Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 81. Rest of Europe Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 82. MEA Kinase Inhibitors, by Country USD Million (2013-2018)
  • Table 83. MEA Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 84. MEA Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 85. MEA Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 86. Middle East Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 87. Middle East Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 88. Middle East Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 89. Africa Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 90. Africa Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 91. Africa Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 92. North America Kinase Inhibitors, by Country USD Million (2013-2018)
  • Table 93. North America Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 94. North America Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 95. North America Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 96. United States Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 97. United States Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 98. United States Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 99. Canada Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 100. Canada Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 101. Canada Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 102. Mexico Kinase Inhibitors, by Type USD Million (2013-2018)
  • Table 103. Mexico Kinase Inhibitors, by Application USD Million (2013-2018)
  • Table 104. Mexico Kinase Inhibitors, by End User USD Million (2013-2018)
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Kinase Inhibitors: by Type(USD Million)
  • Table 116. Kinase Inhibitors Tyrosin Kinase Inhibitors (TKI) , by Region USD Million (2019-2024)
  • Table 117. Kinase Inhibitors Receptor Tyrosine Kinase Inhibitors , by Region USD Million (2019-2024)
  • Table 118. Kinase Inhibitors Non-Receptor Tyrosine Kinase Inhibitors , by Region USD Million (2019-2024)
  • Table 119. Kinase Inhibitors Mulikinase Inhibitors , by Region USD Million (2019-2024)
  • Table 120. Kinase Inhibitors Threonine Kinase Inhibitor , by Region USD Million (2019-2024)
  • Table 121. Kinase Inhibitors RHO Kinase Inhibitors , by Region USD Million (2019-2024)
  • Table 122. Kinase Inhibitors Cyclin Dependant Kinase Inhibitor , by Region USD Million (2019-2024)
  • Table 123. Kinase Inhibitors Aurora Kinase Inhibitors , by Region USD Million (2019-2024)
  • Table 124. Kinase Inhibitors MAP/MEK Kinase Inhibitors , by Region USD Million (2019-2024)
  • Table 125. Kinase Inhibitors Others , by Region USD Million (2019-2024)
  • Table 126. Kinase Inhibitors: by Application(USD Million)
  • Table 127. Kinase Inhibitors Lung Cancer , by Region USD Million (2019-2024)
  • Table 128. Kinase Inhibitors Breast Cancer , by Region USD Million (2019-2024)
  • Table 129. Kinase Inhibitors Renal Cell Cancer , by Region USD Million (2019-2024)
  • Table 130. Kinase Inhibitors Others , by Region USD Million (2019-2024)
  • Table 131. Kinase Inhibitors: by End User(USD Million)
  • Table 132. Kinase Inhibitors Pharmaceutical companies , by Region USD Million (2019-2024)
  • Table 133. Kinase Inhibitors Private and Government research institutes , by Region USD Million (2019-2024)
  • Table 134. Kinase Inhibitors Academic Institutes , by Region USD Million (2019-2024)
  • Table 135. Kinase Inhibitors Healthcare facilities , by Region USD Million (2019-2024)
  • Table 136. South America Kinase Inhibitors, by Country USD Million (2019-2024)
  • Table 137. South America Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 138. South America Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 139. South America Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 140. Brazil Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 141. Brazil Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 142. Brazil Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 143. Argentina Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 144. Argentina Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 145. Argentina Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 146. Rest of South America Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 147. Rest of South America Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 148. Rest of South America Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 149. Asia Pacific Kinase Inhibitors, by Country USD Million (2019-2024)
  • Table 150. Asia Pacific Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 151. Asia Pacific Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 152. Asia Pacific Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 153. China Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 154. China Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 155. China Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 156. Japan Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 157. Japan Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 158. Japan Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 159. India Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 160. India Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 161. India Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 162. South Korea Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 163. South Korea Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 164. South Korea Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 165. Taiwan Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 166. Taiwan Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 167. Taiwan Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 168. Australia Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 169. Australia Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 170. Australia Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 171. Rest of Asia-Pacific Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 172. Rest of Asia-Pacific Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 173. Rest of Asia-Pacific Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 174. Europe Kinase Inhibitors, by Country USD Million (2019-2024)
  • Table 175. Europe Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 176. Europe Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 177. Europe Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 178. Germany Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 179. Germany Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 180. Germany Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 181. France Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 182. France Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 183. France Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 184. Italy Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 185. Italy Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 186. Italy Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 187. United Kingdom Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 188. United Kingdom Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 189. United Kingdom Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 190. Netherlands Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 191. Netherlands Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 192. Netherlands Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 193. Rest of Europe Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 194. Rest of Europe Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 195. Rest of Europe Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 196. MEA Kinase Inhibitors, by Country USD Million (2019-2024)
  • Table 197. MEA Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 198. MEA Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 199. MEA Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 200. Middle East Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 201. Middle East Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 202. Middle East Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 203. Africa Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 204. Africa Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 205. Africa Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 206. North America Kinase Inhibitors, by Country USD Million (2019-2024)
  • Table 207. North America Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 208. North America Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 209. North America Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 210. United States Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 211. United States Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 212. United States Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 213. Canada Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 214. Canada Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 215. Canada Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 216. Mexico Kinase Inhibitors, by Type USD Million (2019-2024)
  • Table 217. Mexico Kinase Inhibitors, by Application USD Million (2019-2024)
  • Table 218. Mexico Kinase Inhibitors, by End User USD Million (2019-2024)
  • Table 219. Research Programs/Design for This Report
  • Table 220. Key Data Information from Secondary Sources
  • Table 221. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Kinase Inhibitors: by Type USD Million (2013-2018)
  • Figure 5. Global Kinase Inhibitors: by Application USD Million (2013-2018)
  • Figure 6. Global Kinase Inhibitors: by End User USD Million (2013-2018)
  • Figure 7. South America Kinase Inhibitors Share (%), by Country
  • Figure 8. Asia Pacific Kinase Inhibitors Share (%), by Country
  • Figure 9. Europe Kinase Inhibitors Share (%), by Country
  • Figure 10. MEA Kinase Inhibitors Share (%), by Country
  • Figure 11. North America Kinase Inhibitors Share (%), by Country
  • Figure 12. Global Kinase Inhibitors share by Players 2018 (%)
  • Figure 13. Global Kinase Inhibitors share by Players (Top 3) 2018(%)
  • Figure 14. Global Kinase Inhibitors share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Roche Holding AG (Switzerland) Revenue: by Geography 2018
  • Figure 18. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 20. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. AstraZeneca (United Kingdom) Revenue: by Geography 2018
  • Figure 22. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Bayer (Germany) Revenue: by Geography 2018
  • Figure 24. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer (United States) Revenue: by Geography 2018
  • Figure 26. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2018
  • Figure 28. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 29. Bristol-Myers Squibb (United States) Revenue: by Geography 2018
  • Figure 30. Cytrx Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 31. Cytrx Corporation (United States) Revenue: by Geography 2018
  • Figure 32. Eisai Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eisai Inc. (United States) Revenue: by Geography 2018
  • Figure 34. Merck Serono SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Merck Serono SA (Switzerland) Revenue: by Geography 2018
  • Figure 36. Global Kinase Inhibitors: by Type USD Million (2019-2024)
  • Figure 37. Global Kinase Inhibitors: by Application USD Million (2019-2024)
  • Figure 38. Global Kinase Inhibitors: by End User USD Million (2019-2024)
  • Figure 39. South America Kinase Inhibitors Share (%), by Country
  • Figure 40. Asia Pacific Kinase Inhibitors Share (%), by Country
  • Figure 41. Europe Kinase Inhibitors Share (%), by Country
  • Figure 42. MEA Kinase Inhibitors Share (%), by Country
  • Figure 43. North America Kinase Inhibitors Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Roche Holding AG (Switzerland)
  • Novartis (Switzerland)
  • AstraZeneca (United Kingdom)
  • Bayer (Germany)
  • Pfizer (United States)
  • GlaxoSmithKline (United Kingdom)
  • Bristol-Myers Squibb (United States)
  • Cytrx Corporation (United States)
  • Eisai Inc. (United States)
  • Merck Serono SA (Switzerland)
Additional players considered in the study are as follows:
Eton Bioscience Inc. (United States) , Inhibikase Therapeutics, Inc. (United States) ,
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation